Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA.

Klinguer-Hamour C, Strop P, Shah DK, Ducry L, Xu A, Beck A.

MAbs. 2014 Jan-Feb;6(1):18-29. doi: 10.4161/mabs.27437.

2.

Fourth World Antibody-Drug Conjugate Summit: February 29-March 1, 2012, Frankfurt, Germany.

Beck A, Lambert J, Sun M, Lin K.

MAbs. 2012 Nov-Dec;4(6):637-47. doi: 10.4161/mabs.21697. Epub 2012 Aug 22.

3.

World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany.

Beck A, Senter P, Chari R.

MAbs. 2011 Jul-Aug;3(4):331-7. Epub 2011 Jul 1.

4.

6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.

Beck A, Wurch T, Reichert JM.

MAbs. 2011 Mar-Apr;3(2):111-32. Epub 2011 Mar 1.

5.

Keystone Symposium on Antibodies as Drugs: March 27-April 1, 2009, Whistler, BC CA.

Wurch T, Larbouret C, Robert B.

MAbs. 2009 Jul-Aug;1(4):318-25. Epub 2009 Jul 28.

6.

American Association of Pharmaceutical Scientists National Biotechnology Conference Short Course: Translational Challenges in Developing Antibody-Drug Conjugates: May 24, 2012, San Diego, CA.

Thudium K, Bilic S, Leipold D, Mallet W, Kaur S, Meibohm B, Erickson H, Tibbitts J, Zhao H, Gupta M.

MAbs. 2013 Jan-Feb;5(1):5-12. doi: 10.4161/mabs.22909. Epub 2012 Dec 19.

7.

Challenges in the development and manufacturing of antibody-drug conjugates.

Ducry L.

Methods Mol Biol. 2012;899:489-97. doi: 10.1007/978-1-61779-921-1_29.

PMID:
22735971
8.

IBC's 23rd Antibody Engineering and 10th Antibody Therapeutics Conferences and the Annual Meeting of The Antibody Society: December 2-6, 2012, San Diego, CA.

Marquardt J, Begent RH, Chester K, Huston JS, Bradbury A, Scott JK, Thorpe PE, Veldman T, Reichert JM, Weiner LM.

MAbs. 2012 Nov-Dec;4(6):648-52. doi: 10.4161/mabs.22221. Epub 2012 Sep 24.

9.

Conference report: hot topics in antibody-drug conjugate development.

Thudium K, Bilic S.

Bioanalysis. 2013 Dec;5(24):2989-93. doi: 10.4155/bio.13.276.

10.

Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.

Adis International Ltd.

Drugs R D. 2003;4(4):243-8.

PMID:
12848590
11.

4th European Antibody Congress 2008: December 1-3, 2008, Geneva, Switzerland.

Beck A, Hanala S, Reichert JM.

MAbs. 2009 Mar-Apr;1(2):93-103. Epub 2009 Mar 20.

12.

The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics.

Gerber HP, Koehn FE, Abraham RT.

Nat Prod Rep. 2013 May;30(5):625-39. doi: 10.1039/c3np20113a. Review.

PMID:
23525375
13.

[Antibody-drug conjugates: a new therapeutic class?].

Chofflon I, Dietrich PY, Thang NN.

Rev Med Suisse. 2013 May 22;9(387):1080-2, 1084-6. French.

PMID:
23757915
14.

Lasofoxifene: CP 336156, CP-336156.

[No authors listed]

Drugs R D. 2005;6(1):56-60. Review.

PMID:
15801869
15.

Antibody-drug conjugates in cancer therapy.

Sievers EL, Senter PD.

Annu Rev Med. 2013;64:15-29. doi: 10.1146/annurev-med-050311-201823. Epub 2012 Oct 3. Review.

PMID:
23043493
16.
17.

9th annual European Antibody Congress, November 11-13, 2013, Geneva, Switzerland.

Reichert JM, Beck A, Lugovskoy AA, Wurch T, Coats S, Brezski RJ.

MAbs. 2014 Mar-Apr;6(2):309-26. doi: 10.4161/mabs.27903. Epub 2014 Jan 17.

PMID:
24492298
18.

Maturing antibody-drug conjugate pipeline hits 30.

Mullard A.

Nat Rev Drug Discov. 2013 May;12(5):329-32. doi: 10.1038/nrd4009. No abstract available. Erratum in: Nat Rev Drug Discov. 2013 Jun;12(6):483.

PMID:
23629491
19.
20.

Monoclonal antibody therapy of cancer.

Weiner LM.

Semin Oncol. 1999 Oct;26(5 Suppl 14):43-51. Review.

PMID:
10561017

Supplemental Content

Support Center